For heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis…. ANDA 213078, held by Hainan Poly. Bivalirudin.
As of Nov 16, 2026, ANDA 213078 (Bivalirudin), held by Hainan Poly, was first approved by FDA on May 28, 2021, with 0 approved supplements and 0 published complete response letters.
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 28, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters